Public Biopharma Financings Plunge In 2016, But Is It A Sign Of Health?
Executive Summary
There were far fewer follow-on and other non-IPO public biopharma company financings during the first half of 2016 compared with the same period in 2015, but the more normal level of investment may mean that the market for therapeutic companies' stocks is healthier than in recent years.
You may also be interested in...
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.
Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.